Q4 2023 Lantern Pharma Inc Earnings Call

March 18, 2024

You did throughout the meeting.

But after.

And welcome to our fourth quarter and year end 2023 earnings call.

As a reminder, this call is being recorded and all attendees are in a listen only mode. We will open the call for questions and answers after our managements presentation of.

This call is being recorded and all attendees are in a listen only mode. We will open the call for questions and answers after our managements presentation.

A webcast replay of today's conference call will be available on our website at lantern pharma dot com shortly after the call.

We issued a press release after market close today summarizing our financial results and progress across the company for the fourth quarter and year ended December 31 2023.

We issued a press release after market close today summarizing our financial results and progress across the company for the fourth quarter and year ended December 31st 2023.

A copy of this release is available through our website, Atlanta and pharma Dot Com, where you will also find a link to the slides management will be referencing on today's call. We.

A copy of this release is available through our website Atlanta pharma Dot Com, where you will.

Also find a link to the slides management will be referencing on today's call.

We would like to remind everyone that remarks about future expectations performance estimates and prospects constitute forward looking statements for purposes of Safe Harbor provisions under the private Securities Litigation Reform Act of 1995.

Land turn pharma cautions that these forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated.

Lantern pharma cautions that these forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated.

A number of factors could cause actual results to differ materially from those indicated by forward looking statements, including results of clinical trials and the impact of competition.

Additional information concerning factors that could cause actual results to differ materially from those in the forward looking statements can be found in our annual report on Form 10-K for the year ended December 31, 2023, which is on file with the SEC and available on our website.

Additional information concerning factors that could cause actual results to differ materially from those in the forward looking statements can be found in our annual report on Form 10-K for the year ended December 31st 2023, which is on file with the SEC and available on our website.

Or we're looking statements made on this conference call are as of today March 18th 'twenty 'twenty, four and lantern pharma does not intend to update any of these forward looking statements to reflect events from circumstances that occur after today unless required by law.

We're looking statements made on this conference call are as of today March 18th 'twenty 'twenty, four and lantern pharma does not intend to update any of these forward looking statements to reflect events from circumstances that occur after today unless required by law.

The webcast replay of the conference call and webinar will be available on lanterns website.

The webcast replay of the conference call and webinar will be available on lanterns website on.

On today's webcast, we have lantern pharma, CEO, Panna Sharma and CFO David Margrave.

Arnaud will start things off with an overview of lanterns strategy and business model and highlight recent achievements in our operations after which David will discuss our financial results.

Onno will start things off with an overview of lanterns strategy and business model and highlight recent achievements in our operations after which David will discuss our financial results.

This will be followed by some concluding comments from partner and then we'll open the call for Q&A.

I'd now like to turn the call over to punish Sharma, President and CEO of Lantern pharma partner. Please go ahead.

I'd now like to turn the call over to Ponder Sharma, President and CEO of Lantern pharma.

Please go ahead.

Good afternoon, and welcome to our fourth quarter.

Hello, everyone and thank you for joining us this afternoon to hear about our fourth quarter and fiscal year 2023 results and corporate progress as many of you have heard me say in the past computational and AI driven approaches are increasing their presence in usage.

Both large and emerging pharma companies will all facets of drug discovery and development.

<unk> companies for all facets of drug discovery and development.

<unk> leadership, and the innovative use of AI and machine learning to transform costs and timelines and the development of precision oncology therapies should yield significant returns for investors and patients as our industry matures and adopts an AI centric and data first approach to drug development.

<unk> leadership and the innovative use of AI and machine learning to transform costs and timelines in the development of precision oncology therapies should yield significant returns for investors and patients as our industry matures and adopts an AI centric and data first approach to drug development.

2023 was a transformational year for lantern pharma across many measures, we launched multiple clinical trials for our using our AI Dai the drug candidates.

2023 was a transformational year for mentor and pharma across many measures we launched multiple clinical trials for our using our AI guided drug candidates.

With multiple peer reviewed publications and posters for our drug candidates and for our radar AI platform.

<unk> had multiple peer reviewed publications and posters for our drug candidates and for our radar AI platform.

Our AI platform advanced reaching over 60 billion data points last year and now is on the road.

AI platform advanced reaching over 60 billion data points last year and now is on the road to reaching over $100 billion. This year.

Reaching over $100 billion this year.

We had significant.

Efficient expansion.

<unk> expansion of our clinical infrastructure operations team. This allows us to efficiently move our trials forward and maintain control over the data and operations of our clinical assets.

Our clinical infrastructure operations team. This allows us to efficiently move our trials forward.

And maintain control over the data and operations of our clinical assets.

We are also advancing a very exciting new companies Starlight therapeutics, which is entirely focused in CNS cancers, and an area, where there has been no single approved therapy as monotherapy and nearly 18 years, we filed 11 patent applications last year across our drug candidates.

We're also advancing a very exciting new company Starlight therapeutics, which is entirely focused on CNS cancers, and an area, where there has been no single approved therapy as monotherapy and nearly 18 years, we filed 11 patent applications last year across our drug candidates and our platform and we've continued to share.

Platform and we've continued to show very strong focus of fiscal discipline.

So very strong focus of fiscal discipline.

Our team.

As accomplished a lot and it's about 24 people today small, but focused and comprised of leaders at every level high value contributors they've made significant strides over the past quarter and throughout 2023 across all of our programs and also with our AI platform radar.

Radar, which has guided the rapid and efficient development of three drugs into clinical trials at a patient cost that has traditionally been unheard of in our industry. Our team has been focused on executing our mission of transforming these oncology drug discovery and development process, especially.

Radar, which has guided the rapid and efficient development of three AIG guided drugs into clinical trials at a pace and cost that has traditionally been unheard of in our industry. Our team has been focused on executing our mission of transforming the oncology drug discovery and development process, especially.

As we bring our clinical stage drug candidates into human clinical trials two that are now in phase one as part of our synthetically Valerie franchise and one that is in phase III.

All of our clinical trials now have enrolled and dosed patients and we expect to have data to share with you later this year as enrolment progresses.

Our team and many clinicians are particularly excited about and interested in the programs for our first in human drug candidates LP 184, and <unk> hundred 84.

Our team and many clinicians are particularly excited about and interested in the program for our first in human drug candidates LP 184, and <unk> 84.

Also our unique drug LP 300, which we in licensed and rescued is aimed at never smokers, who have been impacted by non small cell lung cancer, but it failed other treatment options.

So our unique drug <unk> 300, which we in licensed and rescued is aimed at never smokers, who have been impacted by non small cell lung cancer, but a sale other treatment options.

Lung cancer, among never smokers, a growing problem not only in the U S but globally.

Lung cancer, among never smokers, the growing problem not only in the U S but globally.

And we've been successful in moving towards regulatory allowance for commencing our trial in Japan, Taiwan, and South Korea, where the incidence of non small cell lung cancer. Among never smokers is nearly two and a half to three times that here in the U S.

We've been successful in moving towards regulatory allowance for commencing our trial in Japan, Taiwan, and South Korea, where the incidence of non small cell lung cancer. Among never smokers is nearly two five to three times that here in the U S.

We also continue to make significant progress on the launch of our clinical stage.

CNS in brain cancer focused subsidiary Starlight Therapeutics.

CNS and brain cancer focused subsidiary Starlight Therapeutics.

This is a company that has been largely developed as a result of data AI.

This is a company that has been largely developed as a result of the data.

AI methods computational approaches to optimize and maximize our insights about a molecule like.

About a year ago, we announced the formation of the subsidiary we recruited a CMO last quarter in the fourth quarter and now we are preparing to go into phase <unk> clinical trials.

About a year ago, we announced the formation of the subsidiary we recruited I'd CMO last quarter in the fourth quarter and now we are preparing to go into phase <unk> clinical trials.

We've also made major progress in developing the next major leg of our discovery efforts, where should we focus on drug conjugates, including antibody drug conjugates, specifically would now engineered decrypted <unk> linked antibody drug conjugate, which we're developing in a highly efficient manner with our collaborative partners academic partners and <unk>.

We've also made major progress in developing the next major leg of our discovery efforts, we should we focus on drug conjugates, including antibody drug conjugates, specifically would now engineered a cryptic <unk> linked antibody drug conjugate, which we're developing in a highly efficient manner with our collaborative partners academic partners and.

Germany.

Denis.

I'll talk a little bit.

I'll talk a little bit more.

More about that later in this call.

Our progress across our preclinical assets and our clinical programs has been very focused very efficient and wasn't a large part guided by our AI platforms latest functionality capability and modules modules like our antibody drug conjugate module, we released some exciting data earlier this quarter.

Our progress across our preclinical assets and our clinical programs has been very focused very efficient and was in large part guided by our AI platforms latest functionality capability and modules modules like our antibody drug conjugate module, we released some exciting data earlier this quarter.

Which we concluded as part of our collaboration with University of <unk> field.

Which we concluded as part of our collaboration with University Abella field.

But in particular in that collaboration we found that we had excellent control over the <unk> engineered proteins and that allowed us to have great control of the bio conjugation process and we also saw very high.

And in particular in that collaboration we found that we had excellent control over the <unk> engineered proteins and that allowed us to have great control of the bio conjugation process and we also saw very high.

Potency in the Picomolar range across six solid tumors many of them with.

Huge clinical need in particular and medium expressing her two cancers, which is a real.

Huge clinical need in particular in medium expressing her two cancers, which is a real.

Unmet need in cancer care.

Additionally, we continue to enhance and develop our AI platform for cancer drug development radar. Our platform. We think is revolutionizing the way, we model predict and understand drug cancer interactions, enabling us to advance our newly developed drug programs from initial insights to first in human clinical trials and an average of <unk>.

Additionally, we continue to enhance and develop our AI platform for <unk> cancer drug development radar. Our platform. We think is revolutionizing the way, we model predict and understand drug cancer interactions, enabling us to advance our newly developed drug programs from initial insights to first in human clinical trials and an average of less than two <unk>.

For two years and at a cost of under $2 million per program. It's a milestone unheard of in the realm of oncology drug discovery.

Years, and at a cost of under $2 million per program. It's a milestone unheard of in the realm of oncology drug discovery.

Our leadership in the innovative use of AI and machine learning to transform costs and timelines.

Has allowed us to bring three molecules to market with teams costs and efficiency that is only beginning to make a massive impact we think year over year will continue to make improvements and continue to refine and make our process more efficient more precise and potentially even more powerful during.

Has allowed us to bring three molecules to market with teams cost and efficiency that is only beginning to make a massive impact we think year over year will continue to make improvements and continue to refine and make our process more efficient more precise and potentially even more powerful during 2023, we achieved our goal.

During 2023, we achieved our goal of reaching 60 billion data points growing that cancer focused data more in one year than we had in the prior three years. We expect these massive leaps these increasing the pace to continue and our team expects to reach over $100 billion. This year and this data growth and data ingestion will be automd.

Reaching 60 billion data points grind that cancer focused data of more than one year than we had in the prior three years.

We expect these massive leaps.

Increasing the pace to continue and our team expects to reach over $100 billion. This year and this data growth and data ingestion will be automated it will free up our teams to focus more on intelligent curation and analysis and also on creating upstream engineered datasets from the raw data to solve more specific problems that.

It it will free up our team to focus more on intelligent curation and analysis and also on creating upstream engineered data sets from the raw data to solve more specific problems that can make use of generative AI and generative models.

Can make use of generative AI and generative models.

This golden age of AI Medicine is just beginning and it's being powered by large scale highly available computing power massive data storage and additionally, it is being fed by healthcare patient cancer data all of this data, which is more widely available at an increasing levels of quality.

Higher than ever before.

We believe the companies that harnesses capabilities in biotech.

And more appropriately really the tech bio industry will become long term leaders that create massive value for patients for investors and for our industry.

Lantern pharma is among the leaders in this transformation of the pes risk and cost of oncology drug discovery and development. This transformation has the promise to not only make medicines faster cheaper and with increased precision for patients, but also to help change the direction of R&D productivity and output in the pharma industry.

In the past three years, we have successfully developed and launched 11 additional programs or <unk>.

In the past three years, we have successfully developed and launched 11 additional programs a testament to the agility efficiency and groundbreaking nature of our approach on average. These programs are advancing from initial AI insights to first in human clinical trials in just two and a half years and an average cost of $2 million.

Testament to the agility efficiency and groundbreaking nature of our approach on average. These programs are advancing from initial AI insights to first in human clinical trials in just two and a half years and an average cost of $2 million per program metrics unheard of in oncology drug discovery and.

Her program metrics unheard of in oncology drug discovery in fact in a recent study published by drug discovery today. It was reported that nearly half of the 16 largest pharma companies had negative R&D productivity over the last.

In fact in a recent study published by drug discovery today. It was reported that nearly half of the 16 largest pharma companies had negative R&D productivity over the last.

18 to 20 years with big pharma collectively spending close to 3 billion per drug approval.

18 to 20 years with big pharma collectively spending close to $3 billion for drug approval. These.

These are startling figures and they serve as a stark reminder, that the traditional model with big pharma R&D is not a sustainable our effective strategy and it is not the right approach to improve drug pricing where drug availability with.

These are startling figures and they serve as a stark reminder, that the traditional model of big pharma R&D is not a sustainable our effective strategy and it is not the right approach to improve drug pricing where drug availability.

With escalating economic and political pressures over drug prices, it's clear that our industry needs to rethink its approach fundamentally and we believe big pharma will increase adoption of AI and computational approaches data first approaches to elevate above this major hurdle sitting in front of us.

Now these specific instances of value creation, along with the development of an entirely new company, which will be a clinical stage Starlight, whose sole focus will be on these intractable CNS and brain cancers demonstrates that lantern continues to be at the forefront of a transformative approach to oncology drug discovery, we're reaching speeds.

Inefficiency that we believe are setting new standards in developing cancer medicines.

And efficiency that we believe are setting new standards in developing cancer medicines.

As we continue to accelerate the pace at which we're developing and validating insights that can lead to meaningful drug assets that we can partner license sell in the future.

As we continue to accelerate the pace at which we're developing and validating insights that can lead to meaningful drug assets that we can partner license to sell in the future.

We believe that we're very well positioned to partner these drug assets out to larger companies.

At the same time, our CFO, David <unk> will cover shortly we have a very strong cash position of approximately 43 million 41, $41 3 million in cash cash equivalents and marketable securities and we are.

At the same time, our CFO, David Margrave will cover shortly we have a very strong cash position of approximately 43 million 41, $41 3 million in cash cash equivalents and marketable securities and we are.

Carefully utilizing that to make meaningful progress in a disciplined manner. We are going after indications that are needed.

Going after studies that help validate insights and we're collecting data that will power our portfolio.

We believe our approach is the future of developing cancer therapies, where data can be used to rapidly accelerate programs derisk. The identification of cancer subtypes, most likely to be responsive use biomarker profiling to figure patient profiles and needs out earlier in the process and progress these potentially life changing medicine.

And with economics that have not been seen in our industry.

Now, let's turn to some specific highlights of our financial results during the fourth quarter and for the year end 2023, I'll now turn the call over to our CFO, David Margaret who will provide an overview of our second quarter financial results over the fourth quarter.

Financial results David.

Thank you Panna and good afternoon, everyone.

I'll now share some financial highlights from our fourth quarter and full year ended December 31 2023.

Now share some financial highlights from our fourth quarter and full year ended December 31 2023.

I'll start with a review of the fourth quarter.

Our general and administrative expenses were approximately $1 3 million for the fourth quarter of 2023 down somewhat from approximately $1 6 million in the prior year period.

R&D expenses were approximately $3 6 million for the fourth quarter of 2023 up from approximately $2 3 million in the fourth quarter of 2022.

We recorded a net loss of approximately $4 2 million for the fourth quarter of 2023, or <unk> 49 per share compared to a net loss of approximately $3 4 million or <unk> 31 per share for the fourth quarter of 2022.

For the full year 2023, our R&D expenses were approximately $11 9 million up from approximately $8 6 million for 2022.

This increase was primarily attributable to increases in research studies of approximately $2 $9 8 million.

Increases in research and development payroll expenses of approximately $1 2 million.

Increases in research and development payroll expenses of approximately $1 2 million and increases in consulting expenses of approximately $160000.

And increases in consulting expenses of approximately 160000.

These increases were partially offset by decreases in product candidate manufacturing related expenses of approximately 631000 and decreases of approximately 459000 and payments to <unk> therapeutics.

During the year ended December 31, 22, we released an escrow payment of approximately 459002, <unk> therapeutics and there was not a release of escrow payment amounts to <unk>. During the year ended December 31 23.

Manufacturing related expenses for the year ended December 31, 22 were also reduced by 935000 as a result of a payment. We received in July 2022 from one of our service providers in connection with the resolution of a difference of views regarding the service provider agreement.

Our general and administrative expenses for 2023 were approximately 6.0 million up slightly from $5 9 million for 2022 the.

Our general and administrative expenses for 2023 were approximately 6.0 million up slightly from $5 9 million for 2022. The increase was primarily attributable to increases in payroll and compensation expense and other professional fees.

The increase was primarily attributable to increases in payroll and compensation expense and other professional fees.

Our R&D expenses continue to exceed our G&A expenses by a strong margin, reflecting our focus on advancing our product candidates and pipeline.

Our R&D expenses continued to exceed our G&A expenses by a strong margin, reflecting our focus on advancing our product candidates and pipeline.

For the full year 2023, net loss was approximately $15 $96 million for $1 47 per share compared to $14 3 million.

For the full year 2023, net loss was approximately $15 $9 6 million from $1 47 per share compared to $14 3 million or.

Our $1 31 per share for 2022 or.

Our $1 31 per share for 2022.

Our loss from operations in the 2023 calendar year was partially offset by interest income and other income net totaling approximately $1 9 million.

Our cash position, which includes cash equivalents in marketable securities was approximately $41 3 million as of December 31, 2023.

We anticipate this balance will provide us with a cash runway into at least Q3 of 2025.

Importantly, we believe our solid financial position will fuel continued growth and evolution of our radar AI platform accelerate the development of our portfolio of targeted oncology drug candidates and allow us to introduce additional targeted programs and collaboration opportunities in a capital efficient manner.

As of December 31, 2023, we had 10 million seven 721192 shares of common stock outstanding.

As of December 31, 2023, we had 10 million seven 721192 shares of common stock outstanding outs.

Outstanding warrants to purchase 177998 shares.

Outstanding warrants to purchase 177998 shares and outstanding options to purchase 1 million 91196 shares.

The outstanding options to purchase 1 million 91196 shares.

These warrants and options combined with our outstanding shares of common stock gives us a total fully diluted shares outstanding of approximately $11 nine 9 million shares.

As of year end 2023.

In November of 'twenty, three we were able to reduce our outstanding share count through the purchase of 145348 shares of Landstar common stock at a purchase price of $3 44 per share.

In November of 'twenty three.

We were able to reduce our outstanding share count through the purchase of 145348 shares of <unk> common stock at a purchase price of $3 44 per share.

Our team continues to be very productive under our hybrid operating model.

Our team continues to be very productive under our hybrid operating model. We currently have 21 employees and three FTE consultants focused primarily on leading and advancing our research and drug development efforts. We see this number expanding slightly in coming quarters as we add additional experienced in <unk>.

We currently have 21 employees and three FTE consultants focus primarily on leading and advancing our research and drug development efforts. We see this number expanding slightly in coming quarters as we add additional experienced and talented individuals to help advance our mission.

<unk> individuals to help advance our mission.

I'll now turn the call back over to partner for an update on some of our development programs.

I'll now turn the call back over to partner for an update on some of our development programs Anna.

Thank you David.

As we mentioned earlier in the call.

One of the areas that we're very excited about his starlight therapeutics, we hired Dr. Marc Chamberlain during the fourth quarter and has made excellent progress on advancing our clinical trial design in both adult and pediatric CNS cancers, and we expect to launch the initial adult trial during the second half of this year. This is incumbent on getting the type of safety and early.

The areas that we're very excited about it Starlight therapeutics, we hired Dr. Marc Chamberlain during the fourth quarter and he has made excellent progress on advancing our clinical trial design in both adult and pediatric CNS cancers, and we expect to launch the initial adult trial during the second half of this year. This is incumbent on getting the type of safety and early <unk>.

Efficacy signal from our current ongoing <unk> hundred 84 trial, which is in phase one and it's at this point over halfway enrolled we will share more on the progress of this clinical trial in the coming weeks.

Vacancy signal from our current ongoing LTE 184 trial, which is in phase one and it's at this point over halfway enrolled we will share more on the progress of this clinical trial in the coming weeks.

Now stern, let's focus on CNS cancers came from initial screens to look at cancers that exhibited exquisite preclinical and in silica based.

I'll start let's focus on CNS cancers came from initial screens to look at cancers that exhibited.

The preclinical and in silica based.

<unk>.

Evidence of.

Evidence.

Our sensitivity to LP 184.

Our sensitivity to LP <unk> 84.

It was essentially <unk>.

Born.

From billions of data points.

And we.

We had not yet gone to in vitro and in vivo observations, we naturally moved quickly to in vitro and in vivo observations as it was clear that the data was suggesting that GBM and actually several other brain cancers should be very sensitive given the genomic profile given the interact on design.

And given the.

Levels of DNA damage repair or <unk>, we saw in those <unk>.

Levels of DNA damage repair or <unk>, we saw in those brain cancers.

Brain cancers.

Okay.

Now, let me share some background about the Starlight, which is 100% owned by lantern put and of course, our shareholders and we believe we will have the potential to be another very positive impact on our investors as we monetize this unique asset.

Now, let me share some background about the Starlight, which is 100% owned by lantern put and of course, our shareholders and we believe will have the potential to be another very positive impact on our investors as we monetize this unique asset.

The patents and of course the insights.

Sterling Therapeutics.

It's targeted at several.

Is targeted at several.

Cancers, both adult and pediatric the five year survival rate in many of these cancers is super low despite advances in cancer therapies.

We think globally. They are over 500000 patients that we can target. We are an orphan designation already for GBM and <unk>. We also have the rare pediatric disease designation, we have world class collaborators from with Hopkins Ut Health San Antonio.

We think globally there over 500000 patients that we can target we are an orphan designation already for GBM and <unk>. We also have a rare pediatric disease designation, we have world class collaborators with Hopkins Ut Health San Antonio.

And the children's brain tumor network, which is one of our newer.

And the children's brain tumor network, which is one of our newer our collaborators.

Collaborators.

Additionally, there are over 120 types.

Additionally, there are over 120 types of <unk>.

Central nervous system and brain cancers, such a wide open area, although 50% of them do tend to be GBM and other high grade Gliomas and.

Entrail nervous system and brain cancers, such a wide open area, although 50% of them do tend to be GBM and other high grade Gliomas.

And we will be enrolling some of those patients in the early phase <unk> study to determine maximum tolerated dose.

There are many other brain cancers, both primary and secondary that started light has an option of going after and we think this can be a pivotal pivotal drug startup of <unk> and the future of brain cancer therapies.

There are many other brain cancers, both primary and secondary that Sterlite has an option of going after and we think this can be a pivotal pivotal drug startup or one in the future of brain cancer therapies.

Now, let's talk a little bit about the trials that are planned for startup of <unk> hundred one as I mentioned, the phase <unk> will be done.

Now, let's talk a little bit about the trials that are planned for startup below one as I mentioned the phase <unk> will be done.

By Lanter, the dosage and safety data obtained in the phase one trial, which is now about halfway through will be used to advance the indications for future phase one b slash II trial can be sponsored jointly by lantern and our wholly owned subsidiary of Sterlite Therapeutics.

The markets, we think globally are in excess of $5 billion and this brings the total market for <unk> hundred 80 fours indications both in CNS and in other solid tumors to being in the range of about 10 to 12 plus billion.

So you can see why we're particularly excited about this molecule why we spent a lot of time understanding its molecular profile understanding the triggers of patient response understanding the indications will be most sensitive and then also developing patents around combining this unique drug with other therapies.

So this is one of the most well characterized molecules prior to even getting into the phase one little and now once we received the phase one data.

So this is one of the most well characterized molecules prior to even getting into the phase one let alone now once we received the phase one data.

We're very excited about this molecule we will have data this year on the phase one trial and more importantly, we'll have data that allow us to go into combination trials and into CNS with Starwood therapeutics.

We're very excited about this molecule we will have data this year.

On the phase one trial and more importantly, we will have data that allow us to go into combination trials and into CNS with Sterlite therapeutics.

Let's go to another area that our team has been working on and this is the highly promising area of antibody drug conjugates. This is a very expensive area, which we believe we are going to crush the cost not only in early stage development, perhaps but also in later stage development. It's a high growth area for oncology earlier this year, we announced our advancements of the ADC program that.

Let's go to another area that our team has been working on and this is the highly promising area of antibody drug conjugates.

Very expensive area, which we believe were going to crush the cost not only in early stage development, perhaps but also in later stage development. It's a high growth area for oncology earlier. This year, we announced our advancements of the ADC program that we're working on in combination with the University of <unk> in Germany. Much of this work was accomplished in late 'twenty three at Dr. <unk>.

We're working on in combination with the University of <unk> in Germany. Much of this work was accomplished in late 'twenty three at Dr. <unk> lab as part of the Magic Bullet consortium.

<unk> lab as part of the Magic Bullet consortium.

We were able to.

Take our crypto <unk>.

Antibody drug conjugate.

And advance it not only in proven synthesis and bio conjugation, but develop a preclinical proof of concept that it worked really well in an area of high unmet need which is moderate her two expression or kill rates with this cryptophyte some drug payload averaged 80% across a number of cancer cell lines and more.

In advance it not only in proven synthesis and bio conjugation, but develop a preclinical proof of concept that it worked really well in an area of high unmet need which is moderate her two expression or kill rates with this cryptophyte some drug payload averaged 80% across a number of cancer cell lines and more.

Importantly, we saw that it was about 10 times more potent than some of the existing adcs that used a very common payload.

And then AE.

And then hey.

This is a very very efficient anti tumor activity and more importantly, give us EC 50 values that means we're about 50% of the cells or the cancer.

This is a very very efficient anti tumor activity and more importantly, give us EC 50 values that means we're about 50% of the cells or the cancers.

Cancer cells of interest are killed in the Picomolar to actually single digit nanometer range given the more challenging cancers. We're now doing additional studies to develop and further validate these findings and most importantly, do what we really think is most critical in these studies to obtain a deeper understanding of the genomic and biomarker correlates of.

Cancer cells of interest are killed in the Picomolar to Ashley single digit nanometer range given the more challenging cancers. We're now doing additional studies to develop and further validate these findings and most importantly, do what we really think is most critical in these studies to obtain a deeper understanding of the genomic and biomarker correlates of.

Payload efficacy. This is really one of the most important thing is to understand what is driving that kind of response, how can we repeat it how can we pinpointed and what other things do we need to be aware of the assets. We go after these cancers.

Payload efficacy. This is really one of the most important things is to understand what is driving that kind of response, how can we repeat it how can we pinpointed and what other things do we need to be aware of the assets. We go after these cancers.

So again, we're taking a data first approach. We think this is going to save US a lot of time energy money that can be an asset that we believe can be very licensed <unk> partner will or even spin out after we do store line.

So again, we've got a lot of great assets that are following up to our existing clinical trial assets that are now in phase II and phase one.

I also wanted to take some time on this call to update you on some critical informational updates.

I also wanted to take some time in this call to update you on some critical informational updates a major part of our business is to inform educate and share of the general public.

Major part of our business is to inform educate and share of the general public and.

And with the oncology community and with our stakeholders details about our programs and efforts. It is an area that we want to be better at it as an area we want to focus on.

And we've launched an effort that we're calling webinar Wednesday.

And we launched an effort that we're calling webinar Wednesday.

So our first webinar series.

<unk> will be rolled out we're going to have a webinar.

Will will be rolled out we're going to have a webinar.

As part of this effort.

With Dr. Joseph attribute of Fox Chase Cancer Center, and this will be an LP 300, Dr treat as a leading expert in lung malignancies.

With Dr. Joseph contribute the Fox Chase Cancer Center, and this will be an MLP 300, Dr treat as a leading expert in lung malignancies, and he will be hosting our first webinar in the series in the coming month.

And he will be hosting our first webinar in this series.

In the coming months.

This will be followed by a webinar on Starlight from our very own Dr. Marc Chamberlain is a tremendous resource a virtual human encyclopedia and store of knowledge about CNS and brain cancers, CNS trials history of drugs in CNS and brain cancers history of drug regimens failed and successful across both pediatric and adult CNS cancers.

This will be followed by a webinar on Starlight from our very own Dr. Marc Chamberlain.

A tremendous resource a virtual human encyclopedia and store of knowledge about CNS and brain cancers, CNS trials history of drugs and seen us and brain cancers history of drug regimens failed and successful across both pediatric and adult CNS cancers.

We're very fortunate to have him and he'll be hosting our second webinar focused on starlite and that'll be followed by another webinar about our <unk> hundred 84 clinical trial, which again is about halfway enrolled and that'll be with.

We're very fortunate to have him and he'll be hosting their second webinar focused on starlite and that'll be followed by another webinar about our <unk> hundred 84 clinical trial, which again is about halfway enrolled that will be with <unk>.

Our Fox Chase and I'll focus heavily in pancreatic.

Our Fox Chase and will focus heavily on pancreatic and.

In other cancers challenging tumors that seem to be very responsive to our drug candidate in fact, it seems that the more aggressive. These cancers are recurrent they have higher levels of <unk> and that same markers actually drives the activity of the molecule. So adversely the more aggressive and recurrent.

The better our drug seems to work so far and we're going to now obviously try to design.

Obviously try to design.

Future trials using the data from the phase one and the data we have from our in silicone preclinical work.

As I mentioned earlier, our call this past quarter, our poster for AAC or 2024 was selected it focuses on the phase <unk> clinical trial of <unk> hundred 84, and that will be presented by our very own John Leach out in April 8th and it will focus on <unk> 84, which is a highly potent <unk>.

As I mentioned earlier, our call this past quarter, our poster for ACR 2024 was selected it focuses on the phase <unk> clinical trial of <unk> hundred 84, and there will be presented by our very own John Leach out in April 8th and it will focus on <unk> 84, which is a highly potent <unk>.

Three agnostic mutation agnostic DNA damaging agent in refractory or relapsed lymphoma, and other solid tumors.

53, agnostic mutation agnostic DNA damaging agent in refractory or relapsed lymphomas and other solid tumors.

<unk> hundred 84, as you know, we recently announced that we dosed initial patients and respect expect to bring on many more sites and more patients in the coming quarter.

<unk> hundred 84, as you know, we recently announced that we dosed initial patients and we expect to bring on many more sites and more patients in the coming quarter.

<unk> continues to advance in size scope and capabilities and is also progressing we believe to becoming a standard for AI driven drug development in oncology both for early stage development and later stage patient biomarker in combination therapy identification radar has now surpassed over $60 billion oncology.

Radar continues to advance in size scope and capabilities and is also progressing we believe to becoming a standard for AI driven drug development in oncology both for early stage development and later stage patient biomarker in combination therapy identification radar has now surpassed over $60 billion.

<unk> focused data points.

G focused data points.

And is projected to reach well over $100 billion, we believe by the end of this year.

And is projected to reach well over $100 billion. We believe by the end of this year. The scope of radars data has broadened with the strategic focus on additional classes of compounds, including antibodies checkpoint inhibitors and DNA damaging agents. Additionally data from clinical studies, such as those being obtained from liquid biopsy and data from preclinical.

Scope of radars data has broadened with our strategic focus on additional classes of compounds, including antibodies checkpoint inhibitors and DNA damaging agents. Additionally data from clinical studies, such as those being obtained from liquid biopsy and data from preclinical combination studies that aim to define drug interaction and optimal dosage or being incorporated.

<unk> studies that aim to define drug interaction and optimal dosage are being incorporated into the data points and the data sets the power radar.

Into the data points and the datasets to the power radar.

These data points the associate advancements in automation, along with algorithms and code comprised of functional module and our platform and we believe that we'll have over eight of these modules and all will help us advance and improve.

The speed the precision and the efficiency of radars drug development kind of co pilot and capabilities.

The speed the precision and the efficiency of radars drug development.

Copilot and capabilities.

During the second quarter, we will host a webinar Wednesday.

Discussing the near term roadmap and the use cases for the AI platform radar, which we believe again is the largest and most.

Focused for oncology drug development.

So 2023, it was a pivotal year for us our insights are now entering into patient clinical trials. They started their journey to becoming meaningful therapies in cancer, our collective efforts and dedication have fostered a transformational shift for our company setting us on an exciting trajectory towards a future where we're improving the lives of cancer patients with <unk>.

So 2023 was a pivotal year for us our insights are now entering into patient clinical trials. They started their journey to becoming meaningful therapies in cancer, our collective efforts and dedication have fostered a transformational shift for our company setting us on an exciting trajectory towards a future where we're improving the lives of cancer patients with effective.

<unk>.

And more economically generated treatment options.

With 2024.

We have a lot of other exciting objectives, we expect 2024 to be a breakthrough year for <unk> and our programs specifically we have.

We'd like to share kind of our top 10 milestones.

We want to advance and expand our phase one clinical trial for <unk> hundred 84.

We want to advance and expand our phase one clinical trial for <unk> hundred 84 weeks.

We expect to accelerate enrollment and <unk> 84, and non Hodgkin's lymphomas and some other responsive cancers.

We expect to accelerate enrollment in <unk> hundred 84, and non Hodgkin's lymphoma, and some other responsive cancers we.

We will expand enrollment of harmonic trial into targeted sites in Asia.

The incidence of non small cell lung cancer and never smokers about three times higher.

We're going to explore licensing and partnership capable opportunities with Biopharma companies expanded radar platform to over 100 billion data points and develop additional collaborations with biopharma companies, both large and small but we'll be announcing we also expect to progress Starlight therapeutics towards a phase <unk>.

Adult.

<unk> clinical trial, and perhaps a phase one pediatric trial by early next year or the end of this year.

We also will further our ADC preclinical into IND development to support future partnering or a phase one launch.

We also will further our ADC preclinical into R&D development to support future partnering or a phase one launch.

We're going to develop combination programs for all three of our drugs with existing approved drugs that this is a big area of focus for our platform and four additional trials over the next couple of years, we plan on growing and maturing our clinical operations capabilities and then most importantly continue our discipline.

We're going to develop combination programs for all three of our drugs with existing approved drugs that gives the big area of focus for our platform and four additional trials over the next couple of years, we plan on growing and maturing our our clinical operations capabilities and then most importantly continue our disciplined.

The scope and financial management.

<unk> and financial management.

So we wanted to share those and we'll be providing updates routinely both through <unk>.

So we wanted to share those and we'll be providing updates routinely.

Both through Webinars.

Webinars.

Roadshows investor meetings and in press releases that we believe this is a great year to keep on communications with all of our interested party is very high.

Roadshows investor meetings and in press releases I will do this as a great year to keep on communications with all of our interested party is very high and in closing I also want to express my gratitude to our team.

And in closing I also want to express my gratitude to our team.

Our partners and our stakeholders for their unwavering support.

Together, we are really lighting, the way to the brighter and better future in oncology and solving real world problems with proprietary high value AI solutions that enable rapid development of genomic we targeted therapies.

And at.

At the same time.

Putting a path in place to alter the cost and timeline in drug discovery and we think this places us at the forefront of a new era of development in medicine, what I like to call. The emergence of a golden age in medicine due to AI.

Putting a path in place to alter the cost and timeline in drug discovery and we think this places us at the forefront of a new era of development in medicine would I like to call. The emergence of a golden age in medicine due to AI.

With that I'd like to now open the call for any questions or clarifications.

First question from John Greg question. He asked Adcs have been an important area of acquisition over the last year.

First question from John Great question, Yes, Adcs have been an important area of acquisition over the last year.

<unk> heard broadly that in general M&A conversations have picked up for life Sciences.

<unk> heard broadly that in general M&A conversations that picked up for life Sciences.

Have you observed.

Continued interest in Adcs.

From larger Biopharma is.

I would answer that question, yes, John we have seen interest from actually small and mid size and larger biopharma us in ADC specifically.

I would answer that question is yes, John we have seen interest from actually small and mid size and larger biopharma is in ADC specifically.

And our crypto <unk> ADC.

You know again, it's early a lot of the M&A deals that we saw.

Earlier this year and some in last year. We're in later stage ADC companies many of them actually were already clinical.

Earlier, this year and Sunday last year. We're in later stage ADC companies many of them actually were already clinical.

So it is exciting there is I think not a lot of really unique assets and the adcs I mean, I think most of the payloads almost 70 plus percent of the payloads are all the same.

The designs tend to be very clumped together in terms of the category. So I think the novel target.

Target and plus perhaps in novel payload.

Target and plus perhaps a novel payload.

<unk> with superior potency potency, especially in areas that are overlooked could be of a lot of interest. So I think if you follow all of the data as opposed to a me too approach I think is going to create something valuable.

With superior potency potency, especially in areas that are overlooked could be of a lot of interest. So I think if you follow all the data as opposed to a me too approach I think is going to create something valuable.

Okay.

Great question.

You know as we get more data, we will explore licensing or partnering the asset out as early as possible.

Sure with another question from John.

Sure we have another question from John.

We hinted.

About our radar platform moving now from 5 billion against a couple of years ago to $60 billion.

About our radar platform moving now from $5 billion I guess, a couple of years ago to $60 billion.

Yeah. So the that we're going to have a more detailed platform kind of view day, but the platform now has begun evolving to the point, where it can begin curating ingesting and curating data on its own. So we've gone through the process of what we call campaigns. So we have data ingestion campaigns.

Yes, so the.

We're going to have a more detailed platform kind of view day, but the platform now has begun evolving to the point, where it can be bigger.

Begin curating ingesting and Curating data on its own so we've gone through the process of what we call campaigns. So we have data ingestion campaigns.

We initially were doing this manually.

And as we created kind of Roadmaps are templates for how to ingest the data and what the data structures are like and what the issues are likely of course now trained.

The AI to begin doing this for us.

The AI now has learned a lot of the common datasets and common data conventions and common meta tagging and so the AI is beginning to do the data ingestion. That's a big platform evolution. The AI is also beginning to parametrize, all the algorithms and generate new algorithms.

So our team can now take a step back as the platform basically starts growing in and on itself and so we've also now started a process to do what we called engineered data data that we're extracting from other data that people don't have access to and so this kind of level two data actually is going to be making a lot of insight creation, even more efficient and even <unk>.

So our team can now take a step back is that platform basically starts growing in and on itself and so we have also now started a process to do what we called engineered data data that we're extracting from other data that people don't have access to and so this kind of level two data Ashley it's going to be making a lot of insight creation, even more efficient and even <unk>.

Even more proprietary and we'll talk about that when we talk about our platform.

But yes. The platform has grown its say, it's kind of a different beast now than it was even a year and a half ago and we will continue to evolve.

But yes. The platform has grown its see it's kind of a different beast now than it was even a year and a half ago and will continue to evolve.

We have another question.

This about our buyback and plans for that so David do you want to talk a little bit about sure can we did.

This about our buyback and plans for that so David you want to talk a little bit about sure we did.

Last yes.

This was not it was not a buyback program there was a purchase from two to holders, but we felt this was in the best interest of the company and accretive to shareholders and made since we purchased the 145348 shares.

This was not a it was not a buyback program. There was a purchase from two to holders, but we felt this was in the best interest of the company and accretive to shareholders and made since we purchased the 145348 shares.

At $3 44, a share for an aggregate of right around 500000 and as we described earlier in the call. It's reduced our shares outstanding which we believe is also.

At $3 44, a share for an aggregate of right around 500000 and as we described earlier in the call. It has reduced our shares outstanding which we believe is also.

Beneficial to our holders.

Sure. Thanks, David.

Great. Thanks, David.

Another question.

Sure.

Yeah.

The <unk>.

The.

How are you just about the timing for.

How are you.

About the timing.

For selecting a narrower phase two indication I think again, we allow data to guide the decision process as we get the data from the first.

For selecting a narrower phase two indication I think again, we allow data to guide the decision process as we get the data.

The first.

Set of patients, which is about 35 patients in the phase one a mega slightly over that.

Set of patients, which is about 35 patients in the phase one eight mega slightly over that.

We'll see what the data suggests.

We'll see what the data suggests we.

We certainly have ideas based on our in silica findings in our in vivo work in our animal model work.

And so hopefully it'll support or validate or nullified, but you know data is everything so we'll see what the data suggests about the narrow indications, we think clearly we see that tumor.

And so hopefully it'll support or validate or nullified, but data is everything so we'll see what the data suggests about the narrow indications, we think clearly we see that tumor.

Tumors with DNA damage repair deficiency seem to be very sensitive so.

So we think that will probably be one of the indications and it may be a pan tumor indication.

So we think that will probably be one of the indications that it may be a pan tumor indication.

We've also seen that tumors with high levels of P. T. G. R. One above a certain threshold roughly around 4.2 X of what's in a normal cell also tend to be very sensitive. So that this continues to hold up throughout the trial. Those are two very good kind of Hallmark survey of a characteristic for the indication.

We've also seen that tumors with high levels of <unk> above a certain threshold roughly around four two X whats in a normal cell also tend to be very sensitive. So that this continues to hold up throughout the trial.

Two very good kind of Hallmark survey of a characteristic for the indication. We may go after some targeted indications if we see that things like pancreatic and triple negative breast cancer or even more insensitive and we see that there is a clear need and we think we can do a focused trial.

Now we may go after some targeted indications if we see that things like pancreatic and triple negative breast cancer or even more insensitive and we see that there is a clear need and we think we can do a focused trial.

Obviously bubble up to the top so we'll see what the data suggests and then we'll take a look commercially what is the most efficient way to bring the drug to market.

Next question is.

Do we intend to create further value by creating other companies.

Yeah. That's a great question, we think Starlight is very unique because there's really no company that has focused 100% on a breakthrough new molecule for C&I.

Yeah, that's a great question.

Think starlight is very unique because there's really no company that has focused 100% on a breakthrough new molecule for.

CNS indications, it's the reason, we're able to get a lot of interest around it we've.

CNS indications. It's the reason we were able to get a lot of interest around it we've hit farmers reach out about it we've had biotechs reach out about it.

We've hit farmers reach out about it we've had biotechs reach out about it.

The drug has some very good history in terms of its ability to be proven mechanistic manner in which you can kill in GBM cells, which is an alkylating agent in fact, the only probes has seemed to really work to kill off our Alco later as like Nitro series M. T M Z.

The drug has some very good history in terms of its ability to be proven mechanistic manner in which you can kill in GBM cells, which is an alkylating agent in fact, the only drug that seem to really work to kill off our Alco later as like Nitro series in TMC.

Anything else has had a middling to no effect.

Everything else has had a middling to no effect.

So we're in a good drug class where in a class that has a history of working where in a drug that seems to prefer a cancer cells over any other type of sale it seems to be much more bio available.

So we're in a good drug class where in a class that has a history of working where in a drug that seems to prefer cancer cells over any other type of sale it seems to be much more bio available.

And it seems to be.

Have better blood brain barrier Penetrable 80, then a T.

Have better blood brain barrier penetrant <unk> than.

Kenzie, it seems to be agnostic to MGMT.

And it seems to work in several other brain cancers.

So I think it was a very unique opportunity we have the AI insights with a unique molecule.

We're able to find not just one indication, but a family of kind of indications and so it was really paramount that we launched this effort on its own and get it get it done further and deeper.

We are able to find not just one indication, but a family kind of indications and so it was really paramount that we launched this effort on its own and get it get it done further and deeper.

If we see opportunities like that we will pursue them we have to pursue them I mean, I think adcs could be like that what we're seeing in terms of the early efforts both on our antibody drug conjugate, but also another very exciting space. We're looking at are fragments fragment.

If we see opportunities like that we'll pursue them we have to pursue them I mean, I think adcs could be like that what we're seeing in terms of the early efforts both on our antibody drug conjugate, but also another very exciting space. We're looking at are fragments fragment.

<unk> fragment bodies, and we can actually get even more precision.

Against the antigen or the target of interest in what we call Fred FTC's fragrant drug conjugates and we've begun some very early exploratory work in that area with the.

Against the antigen or the target of interested what we'd call for FTC's fragrant drug conjugates and we began some very early exploratory work in that area with the.

With crypto advice and in other Picomolar agents.

With crypto advice and other Picomolar agents.

So again, we're trying to use the ADC module that we created define targets and then assign something unique in those targets.

So again, we're trying to use the ADC module that we created define targets and then find something unique in those targets.

And then sort of classify both late stage existing antibodies, but also some early stage, where perhaps we can make the process compressed and cheaper and fragrant FTE.

And then sort of classify both late stage existing antibodies, but also some early stage, where perhaps we can make the process compressed and cheaper and.

Fragrant ft.

FTC's can hold that future and then we're also trying to find the right agents that give us.

On the right kind of Dar and improvement in kill rates like we said the crypto <unk> versus the <unk> and other such Teva. It's just it's a lot better kill rate on the cancer cells. So it's.

The right kind of Dar and improvement and kill rates like we said the crypto device versus the MMA ease and other such Teva. It's just it's a lot better kill rate on the cancer cells. So it's.

If we think we can hold that up in <unk>.

Small portfolio of indications again, it could be again, a very great spin out idea or partnering idea very early on.

Small portfolio of indications again, it could be again, a very great Spinout idea, we're partnering idea very early on.

Another question is.

Our own business development opportunities, yes, so we're exploring business development opportunities in three categories.

Our own business development opportunities yeah, So we're exploring business development opportunities in three categories.

Again, I don't like to really talk about deals until deals are really done.

I don't think Theres any point in.

I don't think Theres any point.

Getting people excited about.

Pharma industry, everyone talk to everyone. So yes, we are in discussions with a lot of different companies. It doesn't mean that there may or may not be a deal, but let me walk through our deal ideas that we have that we're working on number one we do expect to announce.

Pharma industry, everyone talks to everyone. So yes, we are in discussions a lot of different companies. It doesn't mean that there may or may not be ideal, but let me walk through our deal ideas that we have that we're working on number one we do expect to announce.

Deals with other biotech companies, where they use our platform and we get certain rights to their to their drugs or develop an effort. So that we are using our platform as currency to help those companies compress the timeline or decrease the risk or increase the ideas around that for their portfolio and we get something in exchange for that and that.

Deals with other biotech companies, where they use our platform and we get certain rights to their to their drugs or development efforts. So that we are using our platform as currency to help those companies compress the timeline or decrease the risk or increase the ideas around that for their portfolio and we get something in exchange for that and that.

It can be done with our platform. The second type of deal that we're beginning to explore and it's in fits and starts but is with big Tech companies Big Tech companies want to have unique platforms that they can offer in the cloud as a service to all their biopharma and academic and research groups.

Can be done with our platform. The second type of deal that we're beginning to explore and it's in fits and starts but is with big Tech companies Big Tech companies want to have unique platforms that they can offer in the cloud as a service to all of their biopharma and academic and research groups. So now Matt Jen radar it can be taken in.

Now in that Gen radar it can be taken into.

<unk>.

One of the Big Tech companies as a platform and you can basically have radar as a service you can have any of these eight modules as a service drug combination blood brain barrier penetrant <unk> drug.

<unk> mechanism of action hunting.

ADC design, so any of these modules and that's what we're trying to really create these unique modules.

ADC designed so any of these modules and that's what we're trying to really create these unique modules.

So again, that's very early in the third one is traditional partnership licensing.

Selling of an asset or a program to big pharma and I think the best way to excite big pharma as a data so will power for the trials will keep options open and share the data and results.

Selling of an asset or a program to big pharma and I think the best way to excite big pharma as a data. So we will power for the trials will keep options open and share the data and results Nick.

Again, we have 11 12 programs now so the likelihood of one of those two are those programs from even more getting licensed or spun out or sold off a partnered I think continues to get higher and higher every quarter.

Thank you for that question.

So with that I'd like to take a moment personally to thank everyone on our team for helping US prepare for these calls and prepare the information we've got a lot of information out in the PR and also in.

The updated slides.

We will have a series of Webinars throughout this year, we have the first three or four actually already kind of been programmed and those webinar. Wednesdays are definitely urge you guys have joined we are very excited about what the future holds for us.

A series of Webinars throughout this year, we have the first three or four actually already kind of in program and this webinar Wednesdays are definitely urge you guys to join we are very excited about what the future holds for us.

We've got number of trials that are ongoing there are a number of exciting programs that we can bring to market either as spinouts or partnered assets and most importantly, the platform begins to grow we're entering a new era of the AI platform. The <unk> platform now is beginning to grow itself.

We've got number of trials that are ongoing there are a number of exciting programs that we can bring to market either spinouts or partnered assets and most importantly, the platform begins to grow we're entering a new era of the AI platform. The <unk> platform now is beginning to grow itself.

And more importantly, we are now, creating new generative AI capabilities around molecular optimization in target selection.

And more importantly, we are now, creating new generative AI capabilities around molecular optimization in target selection things that didn't exist a year ago. So on all fronts. We're growing we maintain fiscal discipline and we've got a significant amount of cash to continue executing our plan and reach milestones for partnering selling license.

That just didn't exist a year ago. So on all fronts, we're growing we maintain fiscal discipline and we've got a significant amount of cash to continue executing our plan and reach milestones for partnering selling licensing.

King.

On our portfolio. So thank you very much and thank you for joining me this afternoon.

Thanks, a lot thank.

Thanks Martin.

Thank you David.

Q4 2023 Lantern Pharma Inc Earnings Call

Request a DemoDemo

LTRN

Lantern Pharma

Earnings